-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $88

Benzinga·10/20/2025 10:40:10
Listen to the news
HC Wainwright & Co. analyst Matthew Caufield maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $72 to $88.